Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families.

Publication date: Jul 18, 2025

Identification of previous SARS-CoV-2 infection typically relies on serology, yet T-cells play a key role in the adaptive immune response against SARS-CoV-2. Here, we investigated in parallel the SARS-CoV-2-specific as well as endemic human coronavirus-specific humoral and cross-reactive cellular responses in children and adults. We analyzed clinical data and blood samples from a family cohort of 96 children and 144 adults at 3-4 and 11-12 months after their first contact with SARS-CoV-2. Humoral response was assessed by a multiplex immunoassay with high sensitivity and specificity (MULTICOV-AB). Cellular responses were analyzed by IFN-γ ELISPOT using four different established epitope compositions (ECs) to discriminate between SARS-CoV-2 specific and HCoV cross-reactive T-cell responses. While the majority of adults had a combined serological and T-cell response, relatively more children had a T-cell response alone rather than a combined response. The magnitude of the T-cell response correlated with symptoms and the humoral response. In addition, SARS-CoV-2 infection significantly boosted the endemic coronavirus-specific cellular response. Overall, our data suggest discordant humoral and cellular responses, reflecting either abortive infection, cellular sensitization with rapid viral clearance or rapid antibody waning or a combination of these phenomena. Restricting epidemiologic analysis to SARS-CoV-2 serological data may underestimate rates of infection with or at least exposure to SARS-CoV-2 in children.

Open Access PDF

Concepts Keywords
Adults Adolescent
Antibody Adult
Coronavirus Antibodies, Viral
Epidemiologic Antibodies, Viral
Months Child
Child, Preschool
COVID-19
Cross Reactions
Female
Humans
Immunity, Cellular
Immunity, Humoral
Infant
Longitudinal Studies
Male
Middle Aged
SARS-CoV-2
T-Lymphocytes
Young Adult

Semantics

Type Source Name
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease IDO role
disease IDO adaptive immune response
disease IDO blood
disease IDO cell
disease MESH infection
disease MESH Tumor
disease MESH Viral Diseases
disease MESH Infectious Diseases
disease MESH Carcinogenesis
disease IDO site
disease IDO immunodeficiency
drug DRUGBANK Coenzyme M
disease MESH Syndrome
disease MESH reinfection
disease MESH Asymptomatic infections
disease IDO symptom
disease MESH dysgeusia
disease MESH dysosmia
disease MESH influenza

Original Article

(Visited 2 times, 1 visits today)